Sign In

Login

Password

Forgot Password ? Sign Up

Metilfenidat (Catalan Wikipedia)

Analysis of information sources in references of the Wikipedia article "Metilfenidat" in Catalan language version.

refsWebsite
Global rank Catalan rank
45nih.gov
4th place
7th place
14web.archive.org
1st place
1st place
3psychiatryonline.org
4,032nd place
5,529th place
2amphetamines.com
low place
low place
2doi.org
2nd place
6th place
2sagepub.com
731st place
661st place
2usdoj.gov
2,755th place
6,816th place
1imshealth.com
low place
low place
1freeuk.com
low place
5,556th place
1elnuevodiario.com.ni
7,288th place
8,203rd place
1nodo50.org
low place
976th place
1antipsychiatry.org
low place
low place
1omim.org
4,380th place
5,891st place
1psychiatrist.com
low place
low place
1incb.org
low place
6,203rd place
1cpementalhealth.com
low place
low place
1thorne.com
low place
5,009th place
1presidioinc.com
low place
low place
1pbs.org
198th place
323rd place
1cbsnews.com
108th place
344th place
1obesityresearch.org
low place
low place
1mallinckrodt.com
low place
low place
1cybrzn.com
low place
low place
1aasmnet.org
low place
low place
1aspetjournals.org
6,663rd place
7,049th place
1dea.gov
8,191st place
low place
1unodc.org
2,494th place
1,286th place
1f-adana.org
low place
low place
1cdc.gov
218th place
281st place
1fundopsi.com.ar
low place
low place
1medicalnewstoday.com
3,011th place
2,879th place
1medpagetoday.com
9,274th place
low place

aasmnet.org

  • Littner M, et al: "Practice parameters for the treatment of narcolepsy: an update for 2000". Sleep. 15 jun 2001;24(4):451-66. PMID: 11403530 | Text complet (PDF) El 1956, Daly i Yoss introduïren l'MFD com a tractament per la narcolepsia. Més tard, n'observaren els efectes en 25 i 36 pacients tractats durant 1-6 mesos amb dosis diàries d'MFD de 40 a 240 mg. Segons Yoss: "La dosi total diària d'MFD hauria de ser tan baixa com 30 mg per la narcolepsia lleu i superior als 100 mg en narcolèpsia greu; a vegades quantitats tan altes com 200 mg són necessàries". Poc després, en un estudi de sèrie de casos dut a terme el 1959, Yoss arribà a utilitzar dosis de 300 mg en un subjecte, sense efectes adversos destacables.

amphetamines.com

antipsychiatry.org

  • Tauber W: "Ritalin: ¿una droga de control social?", a Ekintza Zuzena n.o 26, 2000. Disponible en línea Arxivat 2005-03-09 a Wayback Machine. | Breggin P: "Vital information about Ritalin, attention deficit-hyperactivity disorder and the politics behind the ADHD/Ritalin movement", a The Antipsychiatry Coalition, 1998. Disponible en línea. Consultat a l'agost del 2007.

aspetjournals.org

dmd.aspetjournals.org

  • Markowitz JS, et al: "Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol". Drug Metab Dispos. Jun 2000;28(6):620-4. PMID: 10820132 | Text complet (PDF)

cbsnews.com

  • Trenton NJ: "Adult use of ADHD drugs up. Study: rate of use doubles among group of adults", en HealthWatch, CBS News, 15 set 2005. Disponible en línia. Consultat a l'agost del 2007.

cdc.gov

cpementalhealth.com

cybrzn.com

user.cybrzn.com

dea.gov

doi.org

dx.doi.org

elnuevodiario.com.ni

archivo.elnuevodiario.com.ni

f-adana.org

freeuk.com

critpsynet.freeuk.com

  • Miller T, Leger MC. "A very childish moral panic: Ritalin", Journal of Medical Humanities. 2003 juny ;24(1-2):9-33 Text complet (PDF) (castellà)

fundopsi.com.ar

  • Michanie, Claudio: "Diferencias del Trastorno por Déficit de Atención en el niño y el adulto: consideraciones diagnósticas y terapéuticas". A Moizeszowicz, Julio (ed.): Psicofarmacología Psicodinámica IV - Actualizaciones 2004. Buenos Aires: el autor, 2004. ISBN 987-43-8089-6 | Texto completo (PDF)

imshealth.com

  • "Commonly requested therapeutic class and product information (actualitzat a febrer del 2006)", a IMS Health, IMS National Sales Perspectives, agost del 2006. Disponible en línia

incb.org

  • Green List: Annex to the annual statistical report on psychotropic substances (form P). 23a edició, agost del 2003. International Narcotics Board, Vienna International Centre. Text complet (PDF) Arxivat 2012-08-31 a Wayback Machine.

mallinckrodt.com

bulkpharm.mallinckrodt.com

medicalnewstoday.com

  • Novartis Pharmaceuticals: "Focalin XR(TM) approved for treatment of ADHD in adults, adolescents and children". Medical News Today, 13 jun 2005. Disponible en línea Arxivat 2007-06-30 a Wayback Machine. Consultat a l'octubre del 2007.

medpagetoday.com

  • Peck P: "FDA approves Daytrana transdermal patch for ADHD". MedPage today, 7 abr 2006. Disponible en línea Consultat a l'agost del 2007.

nih.gov

ncbi.nlm.nih.gov

  • "Diagnosis and treatment of attention deficit hyperactivity disorder". NIH Consens Statement. 16-18 de novembre del 1998;16(2):1-37. PMID: 10868163 | Text complet (PDF)
  • Morton WA, Stockton G: "Methylphenidate abuse and psychiatric side effects". Prim Care Companion J Clin Psychiatry. Oct 2000;2(5):159-64. PMID: 15014637 | Text complet (PDF) Arxivat 2006-11-14 a Wayback Machine.
  • Lakhan SE, Hagger-Johnson GE «The impact of prescribed psychotropics on youth». Clin Pract Epidemol Ment Health, 3, 2007, pàg. 21. DOI: 10.1186/1745-0179-3-21. PMC: 2100041. PMID: 17949504.
  • Kidd PM «Attention deficit/hyperactivity disorder (ADHD) in children: rationale for its integrative management» (PDF). Altern Med Rev, 5, 5, Octubre 2000, pàg. 402-428. Arxivat de l'original el 2004-03-13. PMID: 11056411 [Consulta: 26 setembre 2009]. Arxivat 2004-03-13 a Wayback Machine.
  • Weinberg WA, Brumback RA «The myth of attention deficit-hyperactivity disorder: symptoms resulting from multiple causes». J. Child Neurol., 7, 4, Octubre 1992, pàg. 431-445; discussion 446-461. DOI: 10.1177/088307389200700420. PMID: 1469255.[Enllaç no actiu]
  • Vegeu PMID: 16297714
  • Vegeu PMID: 16297714
  • Suter W, et al: "Methylphenidate is not clastogenic in cultured human lymphocytes and in the mouse bone-marrow micronucleus test". Mutat Res. 5 sep 2006;607(2):153-9. PMID: 16829163
  • Walitza S, et al: "Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder?". Environ Health Perspect. Jun 2007;115(6):936-40. PMID: 17589603 | Text complet (PDF)
  • Ouellette EM «Legal issues in the treatment of children with attention deficit hyperactivity disorder». J. Child Neurol., 6 Suppl, 1991, pàg. S68-75. PMID: 2002217.
  • Wallace AE, et al: "Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients". Am J Psychiatry. Jun 1995;152(6):929-31. PMID: 7755127
  • Grade C, et al: "Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study". Arch Phys Med Rehabil. 1998 sep;79(9):1047-50. PMID: 9749682
  • Department of Medicine, Mayo Clinic: Sood A, et al: "Use of methylphenidate in patients with cancer". Am J Hosp Palliat Care. En-feb 2006;23(1):35-40. PMID: 16450661
  • Dalal S, Melzack R: "Psychostimulant drugs potentiate morphine analgesia in the formalin test". J Pain Symptom Manage. Oct 1998;16(4):230-9. PMID: 9803050
  • Hanna A, et al: "A phase II study of methylphenidate for the treatment of fatigue". Support Care Cancer. Mar 2006;14(3):210-5. PMID: 16096772
  • Stoll AL, et al: "Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series". J Clin Psychiatry. Feb 1996;57(2):72-6. PMID: 8591972
  • Leddy JJ, et al: "Influence of methylphenidate on eating in obese men". Obes Res. Feb 2004;12(2):224-32. PMID: 14981214 | Texto completo Arxivat 2008-02-19 a Wayback Machine.
  • Siddall OM: "Use of methylphenidate in traumatic brain injury". Ann Pharmacother. Jul-ag 2005;39(7-8):1309-13. PMID: 15914519
  • Etchepareborda, MC: "Abordaje neurocognitivo y farmacológico de los trastornos específicos del aprendizaje". Rev Neurol. Feb 1999;28 supl 2:S81-93. PMID: 10778495
  • Grubb BP, et al: "The use of methylphenidate in the treatment of refractory neurocardiogenic syncope". Ann Pharmacother. Jul-ag 2005;39(7-8):1309-13. PMID: 8734752
  • Zametkin AJ, et al: "Cerebral glucose metabolism in adults with hyperactivity of childhood onset". N Engl J Med. 15 nov 1990;323(20):1361-6. PMID: 2233902
  • Wilens TE, Spencer TJ: "The stimulants revisited". Child Adolesc Psychiatr Clin N Am. Jul 2000;9(3):573-603, VIII. PMID: 10944658
  • Goede A, et al: "SuperDrug: a conformational drug database". Bioinformatics. 1 de maig del 2005;21(9):1751-3. Epub 2 feb 2005. PMID: 10944658
  • Ding YS, et al: "Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain". Psychopharmacology (Berl). Maig del 1997;131(1):71-8. PMID: 9181638
  • Jensen PS, et al: "Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice". J Am Acad Child Adolesc Psychiatry. May 1999;38(5):557-65. PMID: 10230187
  • Mitler MM, et al: "Narcolepsy and its treatment with stimulants. ASDA standards of practice". Sleep. Jun 1994;17(4):352-71. PMID: 7973321
  • Littner M, et al: "Practice parameters for the treatment of narcolepsy: an update for 2000". Sleep. 15 jun 2001;24(4):451-66. PMID: 11403530 | Text complet (PDF) El 1956, Daly i Yoss introduïren l'MFD com a tractament per la narcolepsia. Més tard, n'observaren els efectes en 25 i 36 pacients tractats durant 1-6 mesos amb dosis diàries d'MFD de 40 a 240 mg. Segons Yoss: "La dosi total diària d'MFD hauria de ser tan baixa com 30 mg per la narcolepsia lleu i superior als 100 mg en narcolèpsia greu; a vegades quantitats tan altes com 200 mg són necessàries". Poc després, en un estudi de sèrie de casos dut a terme el 1959, Yoss arribà a utilitzar dosis de 300 mg en un subjecte, sense efectes adversos destacables.
  • Bymaster FP, et al: "Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex". Psychopharmacology (Berl). Abr 2002;160(4):353-61. PMID: 11919662
  • Markowitz JS, et al: "Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol". Drug Metab Dispos. Jun 2000;28(6):620-4. PMID: 10820132 | Text complet (PDF)
  • Wilens TE, et al: "Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study". J Clin Psychopharmacol. Feb 2004;24(1):36-41. PMID: 14709945
  • Wilens TE, et al: "Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder". J Clin Psychiatry. Feb 2005;66(2):253-9. PMID: 15705013
  • Kooij JJ, et al: "Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial". Psychol Med. Ag 2004;34(6):973-82. PMID: 15554568
  • Palumbo D, et al: "Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy". J Child Adolesc Psychopharmacol. 2004;14(2):185-94. PMID: 15319016
  • Wilens T, et al: "ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study". J Am Acad Child Adolesc Psychiatry. Oct 2005;44(10):1015-23. PMID: 16175106
  • Wilens T, et al: "ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study". J Am Acad Child Adolesc Psychiatry. Oct 2005;44(10):1015-23. PMID: 16175106
  • Fischman MW, et al: "Cardiovascular and subjective effects of intravenous cocaine administration in humans". Arch Gen Psychiatry. 1976 ag;33(8):983-9. PMID: 949232
  • Volkow ND, et al: "Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain". Arch Gen Psychiatry. Juny 1995;52(6):456-63. PMID: 7771915
  • Volkow ND, Swanson JM: "Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD". Am J Psychiatry. Nov 2003;160(11):1909-18. PMID: 14594733 | Text complet (PDF)
  • Mannuzza S, et al: "Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study". J Child Adolesc Psychopharmacol. Tardor del 2003;13(3):273-82). PMID: 14642015
  • Schubiner H, et al: "Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence". Exp Clin Psychopharmacol. Ag 2002;10(3):286-94. PMID: 12233989. (Estudi publicat amb metodologia idònia: doble cec, aleatoritzat, controlat davant placebos.)
  • Levin FR, et al: "Methylphenidate treatment for cocaine abusers with attention-deficit attention-deficit hyperactivity disorder: a pilot study". J Clin Psychiatry. Jun 1998;59(6):300-5. PMID: 9671342. (Estudis oberts, usant MFD d'alliberació prolongada.)

consensus.nih.gov

  • "Diagnosis and treatment of attention deficit hyperactivity disorder". NIH Consens Statement. 16-18 de novembre del 1998;16(2):1-37. PMID: 10868163 | Text complet (PDF)

pubmedcentral.nih.gov

  • Walitza S, et al: "Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder?". Environ Health Perspect. Jun 2007;115(6):936-40. PMID: 17589603 | Text complet (PDF)

nida.nih.gov

nimh.nih.gov

nodo50.org

  • Tauber W: "Ritalin: ¿una droga de control social?", a Ekintza Zuzena n.o 26, 2000. Disponible en línea Arxivat 2005-03-09 a Wayback Machine. | Breggin P: "Vital information about Ritalin, attention deficit-hyperactivity disorder and the politics behind the ADHD/Ritalin movement", a The Antipsychiatry Coalition, 1998. Disponible en línea. Consultat a l'agost del 2007.

obesityresearch.org

omim.org

  • McKusick VA, et al: "Attention deficit-hyperactivity disorder; ADHD", en OMIM - Online Mendelian Inheritance in Man, 26 sept 2006. Vegeu: Mendelian Inheritance in Man (OMIM) 143465

pbs.org

  • "Medicating kids: statistics on stimulant use", en PBS Frontline, 2001. Disponible en línia. Consultat a l'agost del 2007.

presidioinc.com

psychiatrist.com

psychiatryonline.org

ajp.psychiatryonline.org

  • Vegeu Charles Bradley, M.D., 1902–1979 Am J Psychiatry 155:968, juliol del 1998.
  • Bradley C: "Behavior of children receiving Benzedrine". Am J Psychiatry. Nov 1937;94:577-85. Resum(anglès)
  • Volkow ND, Swanson JM: "Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD". Am J Psychiatry. Nov 2003;160(11):1909-18. PMID: 14594733 | Text complet (PDF)

sagepub.com

jcn.sagepub.com

thorne.com

unodc.org

usdoj.gov

deadiversion.usdoj.gov

usdoj.gov

web.archive.org